This trial is testing if a hormone can help reduce symptoms in women with polycystic ovary syndrome.
- Polycystic Ovary Syndrome
1 Primary · 1 Secondary · Reporting Duration: Change occurring over up to 7 days of estradiol administration
Side Effects for
1 Treatment Group
1 of 1
37 Total Participants · 1 Treatment Group
Primary Treatment: Estradiol · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18 - 30 · Female Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What criteria must be met to become eligible for participation in this clinical trial?
"This clinical trial seeks 37 young adult women aged 18-30 with sclerocystic ovaries who exhibit a regular menstrual cycle and no signs of hyperandrogenism. Other eligibility criteria include general good health, aside from being overweight or obese, having PCOS, or adequately treated hypothyroidism. Additionally, participants must agree to utilize reliable non-hormonal birth control methods during the study's duration." - Anonymous Online Contributor
Are there opportunities for new participants in this clinical trial?
"Affirmative. Clinicaltrials.gov states that the scientific trial, initially posted on November 30th 2017, is still open for enrollment. Specifically, 37 individuals from 1 facility need to be recruited for this research project." - Anonymous Online Contributor